Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months

Clinical and Vaccine Immunology

Volumn 20, Issue 12, 2013, Pages 1805-1811

  Hu, Yue Mei ^a   Wang, Xu ^b   Wang, Jun Zhi ^c   Wang, Ling ^d   Zhang, Yong Jie ^a   Chang, Lin ^d   Liang, Zheng Lun ^c   Xia, Jie Lai ^d   Dai, Qi Gang ^a   Hu, Ya Ling ^b   Mao, Qun Ying ^c   Zhu, Feng Cai ^a   Song, Yu Fei ^b   Gao, Fan ^c   Chen, Jiang Ting ^b  

^a Jiangsu Provincial Center for Diseases Prevention and Control   (China)

^b Sinovac Biotech Co Ltd   (China)

^c NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PLACEBO; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; MALE; NAUSEA AND VOMITING; NONHUMAN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SIDE EFFECT; SKIN REDNESS; SWELLING; VACCINE PRODUCTION; VIRUS IDENTIFICATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; CHINA; DOUBLE-BLIND METHOD; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; INFANT; MALE; PLACEBOS; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84888588952     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00491-13     Document Type: Article

References (18)

1. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ. 2000. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin. Infect. Dis. 31:678-683.
2. Chua KB, Chua BH, Lee CS, Chem YK, Ismali N, Kiyu A, Kumarasamy V. 2007. Genetic diversity of enterovirus 71 isolated from cases of hand, foot and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. Malays. J. Pathol. 29:69-78.
3. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. 1999. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N. Engl. J. Med. 341:929-935.
4. Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. 2002. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J. Clin. Microbiol. 40: 2823-2827.
5. Tu PV, Thao NTT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardosa MJ, McMinn PC. 2007. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg. Infect. Dis. 13:1733-1741.
6. Khanh TH, Sabanathan S, Thanh TT, Thoa LPK, Thuong TC, Hang VtT, Farrar J, Hien TT, Chau NvVC, van Doorn HR. 2012. Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg. Infect. Dis. 18:2002-2005.
7. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. 2010. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 7:94. doi:10.1186/1743-422X-7-94.
8. Wang Y, Feng Z, Yang Y, Self S, Gao Y, Longini IM, Wakefield J, Zhang J, Wang L, Chen X, Yao L, Stanaway JD, Wang Z, Yang W. 2011. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology 22:781-792.
9. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. 2012. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 30:3295-3303.
10. Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, Li L, Liang ZL, Zhu FC. 2012. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum. Vaccin. Immunother. 8:668-674.
11. Zhu FC, Wang JZ, Li XL, Liang ZL, Ge HM, Meng FY, Mao QY, Zhang YT, Zhang ZY, Ji H, Gao F, Guo HJ, Zhu QY, Chu K, Wu X, Li JX, Chen QH, Chen XQ, Zhang WW, Hu YM, Li L, Li FX, Yao X, Liu P, Wang H, Shen XL. 2012. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr. Infect. Dis. J. 31:1158-1165.
12. Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, Gao F, Chen QH, Zhu QY, Chu K, Wu X, Yao X, Guo HJ, Chen XQ, Liu P, Dong YY, Li FX, Shen XL, Wang JZ. 2013. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebocontrolled phase 2 clinical trial. Lancet 381:1037-1045.
13. Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, Liang Z, Mao Q, Wang L, Dong C, Liao Y, Guo L, Yang E, Pu J, Yue L, Zhou Z, Li Q. 2013. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 8:e54451. doi:10.1371/journal.pone.0054451.
14. Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, Su IJ, Chong PC, Hsieh SM. 2013. A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31:2471-2476.
15. Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, Yao X, Miao X, Wu X, Li RC, Wang JZ, Yin WD. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 (EV71) vaccine: a phase II, randomized, doubleblind, placebo-controlled trial. J. Infect. Dis., in press. doi:10.1093/infdis/jit429.
16. Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, Shen X, Wang J. 2011. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 29:9668-9674.
17. China Food and Drug Administration (CFDA). 2010. Good manufacturing practice (2010 version). http://www.sda.gov.cn/WS01/CL0053/58 500.html.
18. Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. 2012. Production of EV71 vaccine candidates. Hum. Vaccin. Immunother. 8:1775-1783.